Ventrus Biosciences Inc. recently made known the prices of separate underwritten offerings of 5,800,000 shares of its common stocks. They are looking to receive about $20,000,000 from these offerings.
The company’s Chairman and CEO, Russell H. Ellison, M.D., M.Sc., tells us more through this e-interview with Lead411:
Virtustream will be looking at more product development efforts as well as further expansion in the very near future. This is with the help of their most recent acquisition of $15 million in Series B funding. They have now raised an impressive total of $75 million.
On this particular round of financing, Virtustream also welcomed a new investor – QuestMark Partners. Previous participants like TDF, as well as Columbia Capital, Intel Capital, and Noro‐Moseley Partners also took part in this Series B round.
The company’s Chairman and CEO, Rodney J. Rogers, shares more about this exciting news in this recent e-interview with Lead411: